GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Return-on-Tangible-Asset

HLS Therapeutics (HLS Therapeutics) Return-on-Tangible-Asset : -46.42% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. HLS Therapeutics's annualized Net Income for the quarter that ended in Dec. 2023 was $-21.60 Mil. HLS Therapeutics's average total tangible assets for the quarter that ended in Dec. 2023 was $46.54 Mil. Therefore, HLS Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -46.42%.

The historical rank and industry rank for HLS Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

HLTRF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -58.62   Med: -32.36   Max: 22.97
Current: -58.42

During the past 13 years, HLS Therapeutics's highest Return-on-Tangible-Asset was 22.97%. The lowest was -58.62%. And the median was -32.36%.

HLTRF's Return-on-Tangible-Asset is ranked worse than
84.78% of 1084 companies
in the Drug Manufacturers industry
Industry Median: 1.87 vs HLTRF: -58.42

HLS Therapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for HLS Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Return-on-Tangible-Asset Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.00 -25.96 -26.98 -50.55 -58.98

HLS Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.31 -49.40 -79.31 -58.50 -46.42

Competitive Comparison of HLS Therapeutics's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Return-on-Tangible-Asset falls into.



HLS Therapeutics Return-on-Tangible-Asset Calculation

HLS Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-27.531/( (46.634+46.716)/ 2 )
=-27.531/46.675
=-58.98 %

HLS Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-21.604/( (46.361+46.716)/ 2 )
=-21.604/46.5385
=-46.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


HLS Therapeutics  (OTCPK:HLTRF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


HLS Therapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (HLS Therapeutics) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA 03-21-2013